Managing Director and Chief Executive Officer
Notably, Dr Collier steered ChemGenex Pharmaceuticals from a research-based company with a market capitalisation of $10 million to a company with completed clinical trials and regulatory dossiers submitted to the FDA and EMA. In 2011, Cephalon acquired ChemGenex for $230 million.
Prior to his commercial pharmaceutical career, Dr Collier had an outstanding academic career, highlighted by over 150 peer-reviewed publications and senior authorship on 33 patents. Dr Collier was the inaugural Alfred Deakin Professor at Deakin University, and held positions at Melbourne University, Monash University and University of Toronto. In 2010, Dr Collier was awarded the Roche Award of Excellence for his contribution to the biotechnology industry.
Chief Operating Officer
His experience encompasses marketing, operations and project management across diverse therapeutic areas, including oncology, haematology, cell therapies, fertility and cardiovascular disease. Craig has worked at CSL, Serono UK, Bio Nova International, AVAX Australia and Cryptome Pharmaceuticals, in roles such as Chief Operating Officer, Sales and Marketing Director and Business Unit Manager.
CFO and Company Secretary
Melanie's key experience includes project management of confidential and complex business activities, overall company reporting and compliance with regulatory authorities, restructures, IPOs, M&A and shareholder activities, along with corporate policy development for ASX-listed entities.
Melanie's previous roles include positions in the Office of HRH the Prince of Wales, Global Asset Management, Imperial Cancer Research Fund and The Prince's Foundation. Melanie holds a Bachelor of Communication (Public Relations), and a Graduate Diploma in Applied Corporate Governance. She is an Associate of the Governance Institute of Australia and an Associate of the Institute of Chartered Secretaries (UK).